Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

NCT05021770 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Refractory and Relapsed Primary CNS Lymphoma
PCNSL
Non Hodgkin Lymphoma

Interventions

DRUG: Orelabrutinib
DRUG: Orelabrutinib
DRUG: Thiotepa

Sponsor

Huiqiang Huang

Collaborators

[object Object]